Display options
Cite
Falci DR, Pasqualotto AC. Profile of isavuconazole and its potential in the treatment of severe invasive fungal infections. Infect Drug Resist. 2013;6:163-74doi: 10.2147/IDR.S51340.
Falci, D. R., & Pasqualotto, A. C. (2013). Profile of isavuconazole and its potential in the treatment of severe invasive fungal infections. Infection and drug resistance, 6163-74. https://doi.org/10.2147/IDR.S51340
Falci, Diego R, and Pasqualotto, Alessandro C. "Profile of isavuconazole and its potential in the treatment of severe invasive fungal infections." Infection and drug resistance vol. 6 (2013): 163-74. doi: https://doi.org/10.2147/IDR.S51340
Falci DR, Pasqualotto AC. Profile of isavuconazole and its potential in the treatment of severe invasive fungal infections. Infect Drug Resist. 2013 Oct 22;6:163-74. doi: 10.2147/IDR.S51340. PMID: 24187505; PMCID: PMC3810441.
Copy Download .nbib Format: NLM
Share it on

Infect Drug Resist. 2013 Oct 22;6:163-74. doi: 10.2147/IDR.S51340.

Profile of isavuconazole and its potential in the treatment of severe invasive fungal infections.

Infection and drug resistance

Diego R Falci, Alessandro C Pasqualotto

Affiliations

  1. Hospital Nossa Senhora da Conceição, Porto Alegre, Brazil ; Universidade Federal de Ciências da Saúde de Porto Alegre, Porto Alegre, Brazil.

PMID: 24187505 PMCID: PMC3810441 DOI: 10.2147/IDR.S51340

Abstract

The triazole class of antifungal drugs comprises first-line agents for the treatment of several invasive fungal diseases. Isavuconazole is a novel broad-spectrum triazole agent. Here we summarize its characteristics and compare it with the currently available antifungal agents. Isavuconazole is administered as a prodrug, and it is water soluble. Oral and intravenous formulations are available. Its intravenous formulation does not contain cyclodextrin, which is an advantage over voriconazole, considering the potential for nephrotoxicity of cyclodextrin. As with other azoles, isavuconazole requires a loading dose. Due to its prolonged half-life, a once-a-day regimen is possible. Considering that isavuconazole shares the same mechanism of action with the other triazoles, cross-resistance is an important concern in the class. Tolerability and safety profiles are favorable, and no serious adverse events have been consistently reported. Significant interactions with drugs metabolized by cytochrome P450 are expected to occur, especially with substrates and inducers of the CYP3A4 enzyme. Isavuconazole has in vitro activity against most medically important fungi, including species of Candida, Aspergillus, and Cryptococcus. It has some activity against the agents of mucormycosis. Clinical data regarding isavuconazole remain limited because ongoing trials have not yet been completed or published. Isavuconazole has the potential to become first-line therapy for invasive aspergillosis. It also has the potential for use in the context of antifungal prophylaxis, salvage therapy, or in combination regimens. Results of clinical trials are ultimately expected in order to adequately position isavuconazole in the current antifungal armamentarium.

Keywords: Aspergillus; antifungals; invasive fungal infections; isavuconazole; triazoles

References

  1. Antimicrob Agents Chemother. 2006 Jan;50(1):279-85 - PubMed
  2. J Antimicrob Chemother. 2012 Feb;67(2):362-6 - PubMed
  3. J Antimicrob Chemother. 2006 Jan;57(1):135-8 - PubMed
  4. Antimicrob Agents Chemother. 2003 Sep;47(9):2788-95 - PubMed
  5. J Chemother. 2009 Jun;21(3):272-81 - PubMed
  6. Clin Microbiol Infect. 2009 Oct;15 Suppl 5:71-6 - PubMed
  7. Trends Microbiol. 2010 May;18(5):195-204 - PubMed
  8. Med Mycol. 2009 Feb;47(1):71-6 - PubMed
  9. Antimicrob Agents Chemother. 2007 May;51(5):1818-21 - PubMed
  10. Mycopathologia. 2010 Nov;170(5):291-313 - PubMed
  11. Bioorg Med Chem Lett. 2003 Jan 20;13(2):191-6 - PubMed
  12. J Antimicrob Chemother. 2009 Jul;64(1):79-83 - PubMed
  13. Int J Antimicrob Agents. 2006 Apr;27(4):274-84 - PubMed
  14. Mycoses. 2011 Sep;54(5):e583-9 - PubMed
  15. Antimicrob Agents Chemother. 2002 Jul;46(7):2310-2 - PubMed
  16. Emerg Infect Dis. 2009 Jul;15(7):1068-76 - PubMed
  17. Diagn Microbiol Infect Dis. 2011 Dec;71(4):370-7 - PubMed
  18. J Antimicrob Chemother. 2008 Jan;61 Suppl 1:i19-30 - PubMed
  19. Antimicrob Agents Chemother. 2007 Jul;51(7):2587-90 - PubMed
  20. Expert Opin Investig Drugs. 2009 Sep;18(9):1279-95 - PubMed
  21. Curr Med Res Opin. 2010 Jan;26(1):1-7 - PubMed
  22. Antimicrob Agents Chemother. 2006 Jan;50(1):286-93 - PubMed
  23. Antimicrob Agents Chemother. 2010 Sep;54(9):4012-5 - PubMed
  24. Antimicrob Agents Chemother. 2012 Nov;56(11):6054-6 - PubMed
  25. J Antimicrob Chemother. 2006 Dec;58(6):1198-207 - PubMed
  26. Antimicrob Agents Chemother. 2008 Aug;52(8):2959-61 - PubMed
  27. Antimicrob Agents Chemother. 2009 Jan;53(1):309-11 - PubMed
  28. Antimicrob Agents Chemother. 2009 Aug;53(8):3453-61 - PubMed
  29. Rev Infect Dis. 1990 Mar-Apr;12 Suppl 3:S318-26 - PubMed
  30. Antimicrob Agents Chemother. 2008 Apr;52(4):1396-400 - PubMed
  31. Antimicrob Agents Chemother. 2009 Nov;53(11):4885-90 - PubMed
  32. Antimicrob Agents Chemother. 2008 Apr;52(4):1580-2 - PubMed
  33. J Antimicrob Chemother. 2009 Jan;63(1):161-6 - PubMed
  34. Future Microbiol. 2008 Dec;3(6):603-15 - PubMed
  35. Expert Opin Drug Metab Toxicol. 2012 Jun;8(6):759-65 - PubMed
  36. Antimicrob Agents Chemother. 2011 Dec;55(12):5868-73 - PubMed
  37. Int J Antimicrob Agents. 2011 Dec;38(6):465-73 - PubMed

Publication Types